Your browser doesn't support javascript.
loading
Treatment options for nonalcoholic steatohepatitis - a safety evaluation.
Issa, Danny; Wattacheril, Julia; Sanyal, Arun J.
Affiliation
  • Issa D; a Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine , Virginia Commonwealth University School of Medicine , Richmond , VA , USA.
  • Wattacheril J; b Center for Liver Disease and Transplantation and Division of Digestive and Liver Diseases, Department of Medicine , Columbia University College of Physicians and Surgeons , New York , NY , USA.
  • Sanyal AJ; a Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine , Virginia Commonwealth University School of Medicine , Richmond , VA , USA.
Expert Opin Drug Saf ; 16(8): 903-913, 2017 Aug.
Article in En | MEDLINE | ID: mdl-28641031
ABSTRACT

INTRODUCTION:

There is an urgent as yet unmet need to develop highly effective and safe therapeutics for nonalcoholic fatty liver disease (NAFLD). The remarkable progress in understanding NAFLD pathogenesis allowed the identification of injury pathways which may be recruited as therapy targets. Areas covered This article reviews the safety and tolerability data of the NAFLD therapies and explains the mechanistic basis for each of the established and investigational drugs. Treatment targets include weight loss, anti-metabolic agents such as lipid lowering and anti-diabetic drugs, inflammation, fibrosis and others such as targeting gut microbiota, immune modulation and apoptosis. Expert opinion Current therapies continue to remain suboptimal. Weight loss is effective but hard to achieve. Traditional and endoscopic bariatric procedures are promising although more randomized trials are needed and the long-term safety remains to be established. Clinical trials have demonstrated the efficacy of several drugs for the treatment of NASH. Of these, there remains some uncertainty about the long-term safety of vitamin E. Pioglitazone is associated with osteopenia, fluid retention and weight gain. Obeticholic acid causes pruritus in a substantial proportion of subjects and elafibranor has been associated with transient rises in creatinine. Several exciting therapies are under development and results of clinical and post-marketing trials will help elucidate their safety.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Design / Drugs, Investigational / Non-alcoholic Fatty Liver Disease Type of study: Clinical_trials Limits: Animals / Humans Language: En Journal: Expert Opin Drug Saf Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2017 Document type: Article Affiliation country: United States Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Design / Drugs, Investigational / Non-alcoholic Fatty Liver Disease Type of study: Clinical_trials Limits: Animals / Humans Language: En Journal: Expert Opin Drug Saf Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2017 Document type: Article Affiliation country: United States Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM